Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Abstract Background Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overal...

Full description

Bibliographic Details
Main Authors: Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Cancer
Subjects:
Patient reported outcomes
Health-related quality of life
FACT-MM
Multiple myeloma
Selinexor
Online Access:https://doi.org/10.1186/s12885-021-08453-9

Internet

https://doi.org/10.1186/s12885-021-08453-9

Similar Items